NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analysts give NRx Pharmaceuticals a consensus “Hold” rating, with two sell ratings and five buy ratings among seven firms. The average 12-month price target is $34.50.
• NRx reported a quarterly loss of $0.44 per share, missing the $0.11 consensus estimate, while revenue of $1.10 million also fell short of expectations.
• The stock opened at $3.47, with a 52-week range of $1.62 to $5.05 and a market capitalization of approximately $150.25 million. Institutional and hedge-fund investors own 4.27% of the company.

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received a consensus recommendation of "Hold" from the seven research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $34.50.

A number of research analysts have commented on the stock. Wall Street Zen cut shares of NRx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. BTIG Research restated a "buy" rating and issued a $10.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, August 18th. Zacks Research cut shares of NRx Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 26th. UBS Group reiterated a "buy" rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Bleakley Financial Group LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at about $318,000. Anson Funds Management LP grew its stake in shares of NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company's stock worth $8,249,000 after purchasing an additional 1,018,853 shares during the last quarter. State Street Corp grew its stake in shares of NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company's stock worth $236,000 after purchasing an additional 10,700 shares during the last quarter. Commonwealth Equity Services LLC purchased a new position in NRx Pharmaceuticals during the 4th quarter valued at about $994,000. Finally, Geode Capital Management LLC increased its holdings in NRx Pharmaceuticals by 17.8% during the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company's stock valued at $593,000 after purchasing an additional 33,004 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $3.47 on Wednesday. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The stock has a market cap of $150.25 million, a P/E ratio of -6.31 and a beta of 2.19. The firm's fifty day moving average price is $3.66 and its 200-day moving average price is $3.15.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its earnings results on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. On average, analysts predict that NRx Pharmaceuticals will post -0.36 earnings per share for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.